Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06241183 · ClinicalTrials.gov registry record · Phase 4
Famotidine and Antacids for Treatment of Dyspepsia
A Phase 4 study of GERD and Dyspepsia, sponsored by Stony Brook University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06241183: Recruiting Phase 4 study of GERD and Dyspepsia, sponsored by Stony Brook University.
NCT06241183 is a Phase 4 study of GERD and Dyspepsia that is actively recruiting participants, run by Stony Brook University. The registered enrollment target is 80 participants, below the 162-participant average among 15 other GERD trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06241183, a Phase 4 study of GERD and Dyspepsia, is actively recruiting participants, sponsored by Stony Brook University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.
Primary Outcome
Patients will be asked to rate their pain on a scale of 0 to 10 with 0 indicating no pain and 10 indicating the worst pain imaginable every 15 minutes for 60 minutes.
Conditions Studied
Interventions
- DRUG Intravenous Famotidine
- DRUG Oral Maalox/ Mylanta
Study Locations (1)
New York
- Stony Brook University Hospital - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2025-12 |
| Phase | Phase 4 |
What NCT06241183 shows while recruiting
NCT06241183 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 162-participant average among 15 other GERD trials with a reported enrollment target (51% lower).
The record links to 3 conditions, with GERD appearing as the primary indexed condition, and to 2 interventions - of which Intravenous Famotidine is the first listed.
NCT06241183 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06241183 about?
NCT06241183 is a clinical study titled "Famotidine and Antacids for Treatment of Dyspepsia". The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is ...
What is the current status of trial NCT06241183?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2023-11-09. Estimated completion is 2025-12.
What conditions does trial NCT06241183 study?
This clinical trial studies the following conditions: GERD, Dyspepsia, Acid Reflux.
What interventions are being tested in trial NCT06241183?
The interventions under investigation include: Intravenous Famotidine (DRUG), Oral Maalox/ Mylanta (DRUG).
Who is sponsoring clinical trial NCT06241183?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06241183 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for GERD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06241183's enrollment target sits among peer trials
80 9th of 15 higher than 7 of 15 other GERD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other GERD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mesh Vs Pledgets for Repair of Paraesophageal Hernia
RECRUITING · NA
-
Compassionate Use of Domperidone for Refractory Gastroparesis
RECRUITING · NA
-
Truncal Vagotomy in Patients Undergoing Revisional Sleeve Gastrectomy to Gastric Bypass
RECRUITING · NA
-
The Effect of the Reflux Band™ Upper Esophageal Sphincter (UES) Assist Device on Reflux for Lung Transplant Recipients
RECRUITING · NA
-
Mechanisms Preventing Pharyngeal Reflux
RECRUITING · NA
-
Utility of Mucosal Impedance Device in Chronic Esophageal Disorders:
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI